Over the past decade, several strains (types) of Salmonella typhi have become resistant to multiple antibiotics. Resistant strains have been identified across the globe. However, the 2018 launch of a vaccine has slowed infections. It is estimated that TCV introduction with a catch-up campaign will avert 42.5 million cases and 506,000 deaths caused by fluoroquinolone-resistant typhoid fever, and 21.2 million cases and 342,000 deaths from multidrug-resistant typhoid fever over 10 years following introduction. This episode will cover the impact of vaccinations and the successes and challenges to deploy effective programs.
- Farah Naz Qamar - Pediatric Infectious Disease Associate Professor, The Aga Khan University, Pakistan
- Kathy Neuzil - Director of the Center for Vaccine Development and Global Health, University of Maryland School of Medicine
- Denise Garrett - Vice President, Applied Epidemiology, Sabin Vaccine Institute
- Calman MacLennan - Senior Program Officer, Bacterial Vaccines, Bill and Melinda Gates Foundation
For more information on the impact of typhoid conjugate vaccines and AMR, check out CIDRAP-ASP's report, A Vaccine Is a Bridge: The New Era of Typhoid Prevention.
This podcast is co-created by CIDRAP-ASP and the Antimicrobial Resistance Fighter Coalition (ARFC).
- Artist: Derek Sandbeck
- Song Title: Power Plugs & Superbugs